STOCK TITAN

Repare Therapeutics Inc. Common Shares - $RPTX STOCK NEWS

Welcome to our dedicated page for Repare Therapeutics Common Shares news (Ticker: $RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics Common Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Repare Therapeutics Common Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Repare Therapeutics Common Shares's position in the market.

-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.17%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
Repare Therapeutics Inc. Common Shares

Nasdaq:RPTX

RPTX Rankings

RPTX Stock Data

146.44M
14.92M
1.02%
94.48%
1.61%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAINT-LAURENT

About RPTX

repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.